CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F04%3A00000975" target="_blank" >RIV/00216208:11120/04:00000975 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome
Original language description
Background. CC chemokines mediate leukocyte infiltration into inflamed tissue. We have recently shown that blockade of the CC chemokine receptor CCR1 reduces interstitial inflammation and fibrosis in murine obstructive nephropathy. However, it is not known whether CCR 1 blockade is protective in progressive renal injury associated with severe proteinuria. We therefore studied the effect of the small-molecule CCR1 antagonist BX471 in a murine model of adriamycin-induced focal segmental glomerulosclerosis(FSGS) with nephrotic syndrome and progressive interstitial inflammation and fibrosis. Methods. Adriamycin nephropathy with persistent proteinuria was induced in male BALB/c mice by two intravenous injections of adriamycin (13 mg/kg) at day 0 and 14. BX471 treatment was started at day 14 when proteinuria and interstitial inflammation had developed. At 6 weeks, renal histology was studied by morphometry and immunohistochemistry. Results. At week 6, adriamycin-treated mice showed FSGS, as
Czech name
Blokáda CCR1 snižuje zánětlivou infiltraci a fibrózu intersticia u myší s glomerulosklerózou a nefrotickým syndromem
Czech description
Autoři zkoumali vliv blokátoru CCR1 chemokinového receptoru BX471 u myššího modelu adriamycinem indukované fokálně segmentální glomerulosklerózy, onemocnění charakterizovaného nefrotickým syndromem a progredující fibrózou intersticia ledviny. BX471 výrazně redukuje počet makrofágů a T lymfocytů v intersticiu adriamycinem poškozených ledvin. Počet intersticiálních fibroblastů a objem intersticia ledviny byly léčbou BX471 sníženy oproti neléčenému divokému kmeni, naopak na rozvoj glomerulosklerózy a proteinurie neměla léčba vliv. Blokáda CCR1 může být novou terapeutickou strategií u progresivních nefropatií, jako je FSGS.
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2004
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Kidney International
ISSN
0085-2538
e-ISSN
—
Volume of the periodical
66
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
15
Pages from-to
—
UT code for WoS article
000225026200016
EID of the result in the Scopus database
—